Related Experiment Video

Updated: Sep 19, 2026

High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum
10:19

High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum

Published on: November 23, 2013

Serum IgG antibodies to a 35-kDa P0-related glycoprotein in motor neuron disease

E Nobile-Orazio1, E Manfredini, M Sgarzi

  • 1Institute of Clinical Neurology, Centro Dino Ferrari, Ospedale Maggiore Policlinico, University of Milan, Italy.

Journal of Neuroimmunology
|September 1, 1994
PubMed

Insights

Researchers found a higher frequency of specific serum IgG antibodies in patients with motor neuron disease (MND). These antibodies target a 35-kDa peripheral nerve myelin glycoprotein, suggesting immune system activation in MND.

Area of Science:

  • Neuroimmunology
  • Neuropathology
  • Biochemistry

Background:

  • Motor neuron disease (MND) is a progressive neurodegenerative disorder.
  • The role of the immune system in MND pathogenesis is not fully understood.
  • Peripheral nerve myelin glycoproteins are potential targets in autoimmune neurological conditions.

Purpose of the Study:

  • To investigate the frequency of serum IgG antibodies against a 35-kDa peripheral nerve myelin glycoprotein in patients with MND.
  • To compare antibody prevalence in MND patients with other neurological and non-neurological conditions.
  • To characterize the reacting antigen and its relationship to known myelin proteins.

Main Methods:

  • Immunoblot technique was used to detect serum IgG antibodies.
  • Antibody frequencies were compared across patient groups (MND, neuropathy, other neurological diseases, multiple sclerosis, non-neural immune diseases) and normal subjects.
  • The reacting protein was characterized by molecular mass, reactivity with anti-P0 antiserum, and N-terminal amino acid sequencing.
  • Deglycosylation and dephosphorylation were performed to assess antigen properties.

Main Results:

  • A significantly higher frequency (39%) of serum IgG antibodies to the 35-kDa glycoprotein was observed in MND patients compared to controls (P < 0.005).
  • Elevated antibody levels were also found in patients with neuropathy, multiple sclerosis, and non-neural immune diseases, but were most frequent in MND.
  • The 35-kDa reacting protein showed distinct characteristics from P0 but shared N-terminal amino acid sequence, suggesting a related but distinct antigen.

Conclusions:

  • The frequent occurrence of antibodies to the 35-kDa peripheral nerve myelin glycoprotein in MND supports the hypothesis of immune system activation in this disease.
  • While not definitively pathogenic, these antibodies may serve as biomarkers for immune-mediated processes in MND and other neurological disorders.
  • Further research is warranted to elucidate the precise nature and role of this 35-kDa glycoprotein and associated antibodies in neurological diseases.

More Related Videos

Antibody Binding Specificity for Kappa (V&#954;) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

Primary Cultures of Rat Astrocytes and Microglia and Their Use in the Study of Amyotrophic Lateral Sclerosis09:36

Primary Cultures of Rat Astrocytes and Microglia and Their Use in the Study of Amyotrophic Lateral Sclerosis

Published on: June 23, 2022

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...